JP2008518900A - インダゾール化合物の調製方法 - Google Patents

インダゾール化合物の調製方法 Download PDF

Info

Publication number
JP2008518900A
JP2008518900A JP2007538537A JP2007538537A JP2008518900A JP 2008518900 A JP2008518900 A JP 2008518900A JP 2007538537 A JP2007538537 A JP 2007538537A JP 2007538537 A JP2007538537 A JP 2007538537A JP 2008518900 A JP2008518900 A JP 2008518900A
Authority
JP
Japan
Prior art keywords
compound
formula
reaction
catalyst
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007538537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518900A5 (enExample
Inventor
レイ イワニッキ ブリジット
ジョン フラヒブ エリク
ジュディス カスパリアン アニー
ブライアン ミッチェル マーク
デイヴィッド ペリー マイケル
アン オネイル−スラウェッキ ステイシー
ウィリアム サック ニール
エドワード サエンズ ジェームス
シ ビング
スロボダン スタンコヴィック ネボジュサ
カストゥリ スリランガム ジャヤラム
ティアン クイングピング
ユ シュ
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2008518900A publication Critical patent/JP2008518900A/ja
Publication of JP2008518900A5 publication Critical patent/JP2008518900A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2007538537A 2004-11-02 2005-10-21 インダゾール化合物の調製方法 Withdrawn JP2008518900A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62463504P 2004-11-02 2004-11-02
US71707105P 2005-09-14 2005-09-14
PCT/IB2005/003297 WO2006048744A1 (en) 2004-11-02 2005-10-21 Methods of preparing indazole compounds

Publications (2)

Publication Number Publication Date
JP2008518900A true JP2008518900A (ja) 2008-06-05
JP2008518900A5 JP2008518900A5 (enExample) 2008-11-06

Family

ID=35744929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007538537A Withdrawn JP2008518900A (ja) 2004-11-02 2005-10-21 インダゾール化合物の調製方法

Country Status (14)

Country Link
US (1) US7232910B2 (enExample)
EP (1) EP1809621A1 (enExample)
JP (1) JP2008518900A (enExample)
KR (1) KR20070058690A (enExample)
AR (1) AR051754A1 (enExample)
AU (1) AU2005300310A1 (enExample)
BR (1) BRPI0518203A2 (enExample)
CA (1) CA2586174A1 (enExample)
IL (1) IL182693A0 (enExample)
MX (1) MX2007005291A (enExample)
NO (1) NO20071619L (enExample)
RU (1) RU2007116107A (enExample)
TW (1) TWI294421B (enExample)
WO (1) WO2006048744A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015152117A1 (ja) * 2014-03-31 2015-10-08 千寿製薬株式会社 アルキニルインダゾール誘導体及びその用途
JP2022528994A (ja) * 2019-04-18 2022-06-16 シントン・ビー.ブイ. アキシチニブの製造方法、中間体2-((3-ヨード-1h-インダゾール-6-イル)チオ)-n-メチルベンズアミドの精製方法、アキシチニブ塩酸塩によるアキシチニブの精製方法、アキシチニブ塩酸塩の固体形態

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2134702B2 (en) 2007-04-05 2023-08-30 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
CA2701292C (en) * 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
KR101829595B1 (ko) 2009-01-08 2018-02-14 메르크 파텐트 게엠베하 3-(1-{3-[5-(1-메틸-피페리딘-4일메톡시)-피리미딘-2-일]-벤질}-6-옥소-1,6-디히드로-피리다진-3-일)-벤조니트릴 히드로클로라이드 염의 신규한 다형체 및 이의 제조 방법
KR20140069297A (ko) 2011-09-30 2014-06-09 화이자 인코포레이티드 N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물
JP2014533262A (ja) 2011-11-11 2014-12-11 ファイザー・インク 慢性骨髄性白血病を治療するためのn−メチル−2−[3−((e)−2−ピリジン−2−イル−ビニル)−1h−インダゾール−6−イルスルファニル]−ベンズアミド
US9899120B2 (en) 2012-11-02 2018-02-20 Nanotek Instruments, Inc. Graphene oxide-coated graphitic foil and processes for producing same
US10087073B2 (en) 2013-02-14 2018-10-02 Nanotek Instruments, Inc. Nano graphene platelet-reinforced composite heat sinks and process for producing same
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
CA2932757C (en) * 2013-12-06 2023-10-31 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
AU2015214390B2 (en) 2014-02-04 2020-05-07 Merck Sharp & Dohme LLC. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
EP3522923A1 (en) 2016-10-06 2019-08-14 Pfizer Inc Dosing regimen of avelumab for the treatment of cancer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
CA3254037A1 (en) 2022-03-03 2023-09-07 Pfizer MULTISPECIFIC ANTIBODIES AND THEIR USES
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
RU2357957C2 (ru) * 2003-03-03 2009-06-10 Эррэй Биофарма, Инк. Ингибиторы р38 и способы их применения
MXPA05009303A (es) * 2003-04-03 2005-10-05 Pfizer Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr.
EP1885338A1 (en) 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015152117A1 (ja) * 2014-03-31 2015-10-08 千寿製薬株式会社 アルキニルインダゾール誘導体及びその用途
JPWO2015152117A1 (ja) * 2014-03-31 2017-04-13 千寿製薬株式会社 アルキニルインダゾール誘導体及びその用途
JP2022528994A (ja) * 2019-04-18 2022-06-16 シントン・ビー.ブイ. アキシチニブの製造方法、中間体2-((3-ヨード-1h-インダゾール-6-イル)チオ)-n-メチルベンズアミドの精製方法、アキシチニブ塩酸塩によるアキシチニブの精製方法、アキシチニブ塩酸塩の固体形態
JP7200399B2 (ja) 2019-04-18 2023-01-06 シントン・ビー.ブイ. アキシチニブの製造方法、中間体2-((3-ヨード-1h-インダゾール-6-イル)チオ)-n-メチルベンズアミドの精製方法、アキシチニブ塩酸塩によるアキシチニブの精製方法、アキシチニブ塩酸塩の固体形態

Also Published As

Publication number Publication date
KR20070058690A (ko) 2007-06-08
BRPI0518203A2 (pt) 2009-03-10
NO20071619L (no) 2007-04-25
CA2586174A1 (en) 2006-05-11
MX2007005291A (es) 2007-07-19
TWI294421B (en) 2008-03-11
TW200621721A (en) 2006-07-01
AR051754A1 (es) 2007-02-07
EP1809621A1 (en) 2007-07-25
US20060094881A1 (en) 2006-05-04
US7232910B2 (en) 2007-06-19
RU2007116107A (ru) 2008-11-10
AU2005300310A1 (en) 2006-05-11
IL182693A0 (en) 2007-09-20
WO2006048744A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
JP2008518900A (ja) インダゾール化合物の調製方法
US20070203196A1 (en) Methods of preparing indazole compounds
CN101253163B (zh) 4-氨基-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮化合物的制备方法
CN102177140B (zh) 用于制备苯达莫司汀的方法
CN101094836A (zh) 制备吲唑化合物的方法
JP6267213B2 (ja) 5−(2,6−ジ−4−モルホリニル−4−ピリミジニル)−4−トリフルオロメチルピリジン−2−アミンを製造するための改良された方法
AU2005300311A1 (en) Methods for preparing indazole compounds
CN111278830B (zh) 一种parp抑制剂及其中间体的制备方法
CN111183130A (zh) 苯并杂环衍生物及包含其的医药组合物
CN107176955A (zh) 一种巴瑞替尼的制备方法
CN112585126B (zh) 四环化合物的制备方法
CN101687861A (zh) 用于治疗炎症的吡唑类
CN107207468A (zh) 吡嗪甲酰胺化合物的制造方法及其合成中间体
JP7144873B2 (ja) スガマデクスナトリウム塩の製造方法
JP4820295B2 (ja) イソインドール誘導体の製造方法
JP4624633B2 (ja) カンプトテシンの製造方法
KR101440255B1 (ko) 치환 페닐알칸산의 신규 결정 및 제조 방법
EP2163544A1 (en) Methods of preparing indazole compounds
KR20120113263A (ko) 인다졸-3-카르복실산 및 n-(s)-1-아자바이사이클로[2.2.2]옥트-3-일-1h-인다졸-3-카르복사미드 하이드로클로라이드 염의 제조 방법
WO2003097634A1 (en) Process for producing quinolonecarboxylic acid derivative
TW202328098A (zh) 單環吡啶衍生物的合成中間體之製造方法
HK1113568A (en) Methods for preparing indazole compounds
KR20070085727A (ko) 인다졸 화합물의 제조 방법
WO2004058710A1 (ja) 新規ベンズアミド誘導体及びその製造法
HK1168851B (en) Method for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080918

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20080918

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20080918

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20081024

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090106